Abstract
This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
CNS & Neurological Disorders - Drug Targets
Title:Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study
Volume: 11 Issue: 2
Author(s): Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri
Affiliation:
Keywords: Methotrexate, Docking, Enzyme-Inhibition, Human Brain Acetylcholinestrase, MTX, CTX-M-15, Cephalosporin, Cefotaxime, AChE, Desolvation, Cyclophosphamide, Galantamine
Abstract: This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well known anti-neoplastic drug, methotrexate (MTX) and its comparison to ‘AChE-cyclophosphamide (CP) interactions’ that we reported previously. Docking between MTX and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of MTX within the ‘acyl pocket’ as well as ‘catalytic site’ of AChE to permit docking. However, docking of CP to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of MTX. Scope still remains in the determination of the three-dimensional structure of AChE-MTX complex by X-ray crystallography to validate the described data. The current computational study supports our previous experimental study which concluded a mixed inhibition model for AChE-inhibition by MTX. Furthermore, the present report confirms that MTX is a more efficient inhibitor of human brain AChE compared to CP with reference to Ki and ΔG values.
Export Options
About this article
Cite this article as:
Shazi Shakil, Mohammad A. Kamal, Shams Tabrez, Adel M. Abuzenadah, Adeel G.A. Chaudhary, Ghazi A. Damanhouri , Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study, CNS & Neurological Disorders - Drug Targets 2012; 11 (2) . https://dx.doi.org/10.2174/187152712800269669
DOI https://dx.doi.org/10.2174/187152712800269669 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Suggestion and Pain in Migraine: A Study by Laser Evoked Potentials
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Commentary: Recalling Memory by Brain Stimulation
CNS & Neurological Disorders - Drug Targets Health Anxiety (Hypochondriasis): an Emotional Disorder in An Alternative Taxonomy
Current Psychiatry Reviews Molecular Modeling Studies of Anti-Alzheimer Agents by QSAR, Molecular Docking and Molecular Dynamics Simulations Techniques
Medicinal Chemistry High Risk of One-year Stroke Recurrence in Patients with Younger Age and Prior History of Ischemic Stroke
Current Neurovascular Research A Knock-Down Cell-Based Study for the Functional Analysis of Chloride Intracellular Channel 1 (CLIC1): Integrated Proteomics and Microarray Study
Protein & Peptide Letters The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Brain Metabolism of Ethanol and Alcoholism: An Update
Current Drug Metabolism Intervention of Proliferation and Differentiation of Endogenous Neural Stem Cells in the Neurodegenerative Process of Huntingtons Disease Phenotype
CNS & Neurological Disorders - Drug Targets Omega-3 Fatty Acids and Hippocampal Neurogenesis in Depression
CNS & Neurological Disorders - Drug Targets Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Pharmacologic Treatment with GABAB Receptor Agonist of Methamphetamine-Induced Cognitive Impairment in Mice
Current Neuropharmacology The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Compulsive Buying Disorder: A Review and Update
Current Pharmaceutical Design Nanosuspension Technology: A Strategic Approach for Poorly Soluble Drugs
Nanoscience & Nanotechnology-Asia Transcranial Direct Current Stimulation for Treatment of Auditory Hallucination: A Systematic Review of Clinical Efficacy
Current Psychiatry Reviews Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology